Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Lactobacillus GG in Pediatric Ulcerative Colitis (UC)

This study has been withdrawn prior to enrollment.
(IND for this study remained on clinical hold)
Sponsor:
Information provided by:
Children's Hospital Medical Center, Cincinnati
ClinicalTrials.gov Identifier:
NCT00895336
First received: April 27, 2009
Last updated: February 8, 2011
Last verified: February 2011

April 27, 2009
February 8, 2011
March 2011
March 2012   (final data collection date for primary outcome measure)
The primary endpoint will be a reduction in the fecal calprotectin level following the receipt of study agent. [ Time Frame: after dosing 28 - 35 days with LGG ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00895336 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Lactobacillus GG in Pediatric Ulcerative Colitis (UC)
An Open Label Pilot Study of Lactobacillus GG in Pediatric Ulcerative Colitis

Abstract:

Current evidence suggests that the enteric flora is the primary trigger for chronic mucosal inflammation in the Inflammatory Bowel Diseases (IBD), Crohn's Disease (CD) and Ulcerative Colitis (UC). Studies using probiotic administration to modify the flora for either induction or maintenance of remission in IBD have had mixed results. Whether probiotics may exert an anti-inflammatory effect in IBD is not known. The investigators hypothesize that daily administration of a probiotic, Lactobacillus GG, for four weeks will reduce objective markers of mucosal inflammation in pediatric UC patients. The investigators will enroll 20 UC patients in remission or with mild disease activity. These patients will have a one month period of observation without intervention. They will then receive Lactobacillus GG (Culturelle), 1010 CFU by mouth twice a day for four weeks (28 days). At baseline and Day 28, and at day 56 clinical disease activity will be measured using the Pediatric UC Activity Index (PUCAI), a blood sample for determination of circulating granulocyte pSTAT3+ activation will be obtained, and a stool sample for determination of fecal calprotectin will be obtained. In addition, =the investigators will sample subject saliva to determine salivary glycan phenotype as a surrogate marker of changes of mucosal glycan expression in response to probiotic administration. The investigators anticipate that both circulating granulocyte pSTAT3+ activation and fecal calprotectin, as established biomarkers of colonic inflammation, will be reduced in subjects who receive Lactobacillus GG. Completion of the proposed studies will determine whether Lactobacillus GG reduces mucosal inflammation in pediatric UC, and will provide information to design a larger randomized trial.

The investigators' study design is novel in that it is the first probiotic study in children with UC and it will measure outcomes utilizing the biomarkers fecal calprotectin and pSTAT3+ circulating granulocytes.

Not Provided
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Ulcerative Colitis
Biological: Lactobacillus GG
1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
Other Name: Culturelle
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
20
October 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ability to provide written informed consent (and if applicable, Assent) and comply with study assessments for the full duration of the study;
  • Enrolled without regard to gender, race, ethnicity;
  • Age > 5 years to < 18 years;
  • Diagnosis of Ulcerative Colitis (UC);
  • Remission or mild disease activity defined by a PUCAI <34;
  • Subjects taking stable doses (defined as 30 days) of all UC medications including AZA/6-MP, methotrexate, mesalamine, or infliximab at entry will be included;
  • Willing to use birth control during study participation for females of child-bearing potential, as determined by investigator.

Exclusion Criteria:

  • Current use, or use in the last 3 months, of probiotic preparations, not including yogurt;
  • Known history of HIV or other known immunocompromised disease;
  • Any central vascular line;
  • Concomitant administration of an antibiotic, and must be off antibiotics for at least one month prior to enrollment;
  • Cardiac valvular disease;
  • Any other condition requiring current hospitalization for treatment;
  • Current use of prednisone or budesonide;
  • Diagnosis of Crohn's disease or indeterminate colitis;
  • Pregnancy (positive pregnancy test) prior to enrollment in the study for females of child-bearing potential;
  • Females of child-bearing potential who are unwilling to use birth control during study participation;
  • Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated;
  • Participation in another simultaneous clinical trial involving a drug or biological other than participation in the Pediatric IBD Registry and/or the Pediatric IBD Network for Research and Improvement.
Both
5 Years to 18 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00895336
2009-0443
Yes
Lee Denson, M.D., Cincinnati Childrens
Children's Hospital Medical Center, Cincinnati
Not Provided
Principal Investigator: Lee Denson, M.D. Children's Hospital Medical Center, Cincinnati
Children's Hospital Medical Center, Cincinnati
February 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP